These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 33400747)

  • 1. Targeted liposomal drug delivery: a nanoscience and biophysical perspective.
    Liu Y; Castro Bravo KM; Liu J
    Nanoscale Horiz; 2021 Feb; 6(2):78-94. PubMed ID: 33400747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization.
    Makwana V; Karanjia J; Haselhorst T; Anoopkumar-Dukie S; Rudrawar S
    Int J Pharm; 2021 Jan; 593():120117. PubMed ID: 33259901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pros and cons of the liposome platform in cancer drug targeting.
    Gabizon AA; Shmeeda H; Zalipsky S
    J Liposome Res; 2006; 16(3):175-83. PubMed ID: 16952872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional Liposomes.
    Aryasomayajula B; Salzano G; Torchilin VP
    Methods Mol Biol; 2017; 1530():41-61. PubMed ID: 28150195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review.
    Riaz MK; Riaz MA; Zhang X; Lin C; Wong KH; Chen X; Zhang G; Lu A; Yang Z
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29315231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future directions of liposome- and immunoliposome-based cancer therapeutics.
    Park JW; Benz CC; Martin FJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):196-205. PubMed ID: 15717745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From conventional to stealth liposomes: a new frontier in cancer chemotherapy.
    Cattel L; Ceruti M; Dosio F
    Tumori; 2003; 89(3):237-49. PubMed ID: 12908776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
    Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles.
    Alavi M; Hamidi M
    Drug Metab Pers Ther; 2019 Feb; 34(1):. PubMed ID: 30707682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
    Kibria G; Hatakeyama H; Sato Y; Harashima H
    Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocells: Modular Mesoporous Silica Nanoparticle-Supported Lipid Bilayers for Drug Delivery.
    Butler KS; Durfee PN; Theron C; Ashley CE; Carnes EC; Brinker CJ
    Small; 2016 Apr; 12(16):2173-85. PubMed ID: 26780591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
    Haghiralsadat F; Amoabediny G; Helder MN; Naderinezhad S; Sheikhha MH; Forouzanfar T; Zandieh-Doulabi B
    Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):169-177. PubMed ID: 28376641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive Imaging of Liposomal Delivery of Superparamagnetic Iron Oxide Nanoparticles to Orthotopic Human Breast Tumor in Mice.
    Kato Y; Zhu W; Backer MV; Neoh CC; Hapuarachchige S; Sarkar SK; Backer JM; Artemov D
    Pharm Res; 2015 Nov; 32(11):3746-3755. PubMed ID: 26078000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updates on the use of liposomes for active tumor targeting in cancer therapy.
    Yan W; Leung SS; To KK
    Nanomedicine (Lond); 2020 Feb; 15(3):303-318. PubMed ID: 31802702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlling the size and shape of liposomal ciprofloxacin nanocrystals by varying the lipid bilayer composition and drug to lipid ratio.
    Li T; Clulow AJ; Nowell CJ; Hawley A; Cipolla D; Rades T; Boyd BJ
    J Colloid Interface Sci; 2019 Nov; 555():361-372. PubMed ID: 31398564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
    Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
    J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the synthesis of mucus permeating nanocarriers.
    Bourganis V; Karamanidou T; Samaridou E; Karidi K; Kammona O; Kiparissides C
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):239-49. PubMed ID: 25661586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
    Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
    Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.